Posted by Michael Wonder on 31 Jul 2025
Schedule of Pharmaceutical Benefits - 1 August 2015
1 August 2025 - The August 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The August issue of the Schedule includes has a few new/revised listings of note:
- Denosumab (Wyost, Jubbonti) - new biosimilar medicine
- Durvalumab (Imfinzi) - new indication
- Eflornithine hydrochloride monohydrate (Ifinwil) - new medicine
- Foslevodopa with foscarbidopa (Vyalev) - new combination product
- Omalizumab (Omlyco) - new biosimilar medicine
- Omalizumab (Xolair) - new formulation
- Ustekinumab (Steqeyma) - new biosimilar medicine
Read summary of PBS changes
Posted by:
Michael Wonder